- Home
- MFM vs NBTX Comparison
MFM vs NBTX Comparison
Compare MFM & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFM
- NBTX
- Stock Information
- Founded
- MFM 1986
- NBTX 2003
- Country
- MFM United States
- NBTX France
- Employees
- MFM N/A
- NBTX N/A
- Industry
- MFM Finance Companies
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- MFM Finance
- NBTX Health Care
- Exchange
- MFM Nasdaq
- NBTX Nasdaq
- Market Cap
- MFM 212.1M
- NBTX 211.9M
- IPO Year
- MFM N/A
- NBTX 2020
- Fundamental
- Price
- MFM $5.10
- NBTX $6.69
- Analyst Decision
- MFM
- NBTX Strong Buy
- Analyst Count
- MFM 0
- NBTX 1
- Target Price
- MFM N/A
- NBTX $8.00
- AVG Volume (30 Days)
- MFM 108.1K
- NBTX 6.8K
- Earning Date
- MFM 01-01-0001
- NBTX 09-17-2025
- Dividend Yield
- MFM 4.08%
- NBTX N/A
- EPS Growth
- MFM N/A
- NBTX N/A
- EPS
- MFM 0.03
- NBTX N/A
- Revenue
- MFM N/A
- NBTX N/A
- Revenue This Year
- MFM N/A
- NBTX N/A
- Revenue Next Year
- MFM N/A
- NBTX $221.06
- P/E Ratio
- MFM $176.67
- NBTX N/A
- Revenue Growth
- MFM N/A
- NBTX N/A
- 52 Week Low
- MFM $4.37
- NBTX $2.76
- 52 Week High
- MFM $5.48
- NBTX $7.29
- Technical
- Relative Strength Index (RSI)
- MFM 49.49
- NBTX 69.50
- Support Level
- MFM $5.14
- NBTX $6.49
- Resistance Level
- MFM $5.11
- NBTX $7.15
- Average True Range (ATR)
- MFM 0.05
- NBTX 0.34
- MACD
- MFM 0.00
- NBTX 0.14
- Stochastic Oscillator
- MFM 50.00
- NBTX 74.36
About MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.